Suvorexant: Dual orexin OX1/OX2 receptor antagonist treatment of sleep disorders

Drugs of the Future

Volumn 38, Issue 1, 2013, Pages 27-36

  Radl, S ^a  

^a Zentiva Prague   (Czech Republic)

Author keywords

Insomnia; MK 4305; Orexin receptor antagonist; Sleep apnea; Suvorexant

Indexed keywords

DRUG METABOLITE; FILOREXANT; GSK 649868; MK 6096; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; PLACEBO; SUVOREXANT; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; AREA UNDER THE CURVE; ARTICLE; CATAPLEXY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENANTIOSELECTIVITY; FATIGUE; HEADACHE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYSOMNOGRAPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHEEHAN DISABILITY SCALE; SIDE EFFECT; SLEEP DISORDER; SLEEP WALKING; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TYRER BENZODIAZEPINE WITHDRAWAL QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; WITHDRAWAL SYNDROME;

EID: 84930539587     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.01.1906425     Document Type: Article

References (40)

1. Bergman, J.M., Breslin, M.J., Coleman, P.J., Cox, C.D., Mercer, S.P., Roecker, A.J. (Merck & Co., Inc.) Substituted diazepan compounds as orexin receptor antagonists. CN 101880276, EP 2089382, EP 2392572, JP 201051121, JP 2011068665, JP 2011079848, US 2008132490, US 7951797, US 2011195957, WO 2008069997.
2. Cox, C.D., Breslin, M.J., Whitman, D.B. et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK- 4305) for the treatment of insomnia. J Med Chem 2010, 53(14): 5320-32.
3. Mangion, I.K., Sherry, B.D., Yin, J., Fleitz, F.J. Enantioselective synthesis of a dual orexin receptor antagonist. Org Lett 2012, 14(13): 3458-61.
4. Baxter, C.A., Cleator, E., Brands, K.M.J. et al. The first large-scale synthesis of MK-4305: A dual orexin receptor antagonist for the treatment of sleep disorder. Org Proc Res Dev 2011, 15(2): 367-75.
5. Wallace, D.J. Development of the manufacturing route for suvorexant - A dual orexin antagonist for sleep disorder. 244th ACS Natl Meet Exp (Aug 19-23, Philadelphia) 2012, Abst ORGN-271.
6. Baxter, C.A. Development of the manufacturing route for suvorexant - A dual orexin antagonist for sleep disorder. Balticum Organicum Syntheticum - Intl Conf Org Synth (July 1-4, Tallinn) 2012, p 16.
7. Strotman, N.A., Baxter, C.A., Brands, K.M.J. et al. Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual orexin inhibitor suvorexant (MK-4305). J Am Chem Soc 2011, 133(21): 8362-71.
8. Cleator, E. Discovery of an asymmetric synthesis of suvorexant. 244th ACS Natl Meet Exp (Aug 19-23, Philadelphia) 2012, Abst ORGN-13.
9. Kocienski, P. Synthesis of suvorexant. Synfacts 2011, (8): 822.
10. Wertz, S., Kodama, S., Studer, A. Amination of benzoxazoles and 1,3,4- oxadiazoles using 2,2,6,6-tetramethylpiperidine-N-oxoammonium tetrafluoroborate as an organic oxidant. Angew Chem Int Ed 2011, 50(48): 11511-5.
11. Langmead, C.J., Jerman, J.C., Brough, S.J., Scott, C., Porter, R.A., Herdon, H.J. Characterisation of the binding of 3H-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004, 141(2): 340-6.
12. Scammell, T.E., Winrow, C.J. Orexin receptors: Pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011, 51: 243-66.
13. Smart, D., Jerman, J. The physiology and pharmacology of the orexins. Pharmacol Ther 2002, 94(1-2): 51-61.
14. Smart, D., Haynes, A.C, Williams, G., Arch, J.R. Orexins and the treatment of obesity. Eur J Pharmacol 2002, 440(2-3): 199-212.
15. Mahler, S.V., Smith, R.J., Moorman, D.E., Sartor, G.C., Aston-Jones, G. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 2012, 198: 79-121.
16. Owen, R.T., Castaner, R., Bolós, J., Estivill, C. Almorexant. Drugs Fut 2009, 34(1): 5-10.
17. Sullivan, S. Update on emerging drugs for insomnia. Expert Opin Emerg Drugs 2012, 17(3): 295-8.
18. Hopkins, C.R. Molecule spotlight on suvorexant. ACS Chem Neurosci 2012, 3(9): 647-8.
19. Coleman, P.J., Schreier, J.D., Cox, C.D. et al. Discovery of [(2R,5R)-5-{[(5- fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5- methyl-2-(pyrimidin- 2-yl)phenyl]methanone (MK-6096): A dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012, 7(3): 415-24
20. Girardin, M., Ouellet, S.G., Gauvreau, D. et al. Convergent kilogram scale synthesis of dual orexin receptor antagonist. Org Process Res Dev 2012, 17: in print.
21. Winrow, C., Coleman, P., Cox, C. et al. Preclinical characterization of MK- 4305 - A novel dual orexin receptor antagonist for insomnia. J Sleep Res 2010, 19(Suppl. 2): 195.
22. Winrow, C.J., Kuduk, S., Doran, S.M. et al. Preclinical efficacy of suvorexant and other orexin receptor antagonists. Sleep Biol Rhythms 2011, 9(4): 332.
23. Coleman, P.J., Cox, C.D., Breslin, M.J. et al. Discovery of MK-4305: A novel orexin receptor antagonist for the treatment of insomnia. 239th ACS Natl Meet (March 21-25, San Francisco) 2010, Abst MEDI 37.
24. Winrow, C.J., Gotter, A.L., Cox, C.D. et al. Promotion of sleep by suvorexant - A novel dual orexin receptor antagonist. J Neurogenet 2011, 25(1-2): 52-61.
25. Sun, H., Kennedy, D., Lewis, N. et al. The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305), a dual orexin receptor antagonist, in healthy male subjects. 113th Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 12-17, National Harbor) 2012, Abst PI-59
26. Sun, H., Kennedy, W.D., Lewis, N. et al. The single dose pharmacokinetic and pharmacodynamic profiles of suvorexant (MK-4305), a dual orexin receptor antagonist, in healthy male subjects. Sleep Biol Rhythms 2011, 9(4): 332.
27. Sun, H., Kennedy, W., Lewis, N. et al. Dose effects of MK-4305, a dual orexin receptor antagonist for insomnia, in healthy male subjects. J Sleep Res 2010, 19(Suppl. 2): 199-200.
28. Herring, W.J., Budd, K.S., Hutzelmann, J. et al. Efficacy and tolerability of the dual orexin receptor antagonist MK-4305 in patients with primary insomnia: Randomized, controlled, adaptive crossover polysomnography study. 24th Annu Meet Assoc Sleep Soc (June 5-9, San Antonio) 2010, Abst 0591.
29. Herring, W.J., Budd, K., Hutzelmann, J. et al. Efficacy and tolerability of the dual orexin receptor antagonist MK-4305 in patients with primary insomnia: A randomized, controlled, adaptive crossover polysomnography study. J Sleep Res 2010, 19(Suppl. 2): 44-5.
30. Herring, W.J., Snyder, E., Budd, K. et al. Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant. Neurology 2012, 79(23): 2265-74.
31. Connor, K., Budd, K., Snavely, D. et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: A 3- month phase 3 trial (trial #1). 21st Congr Eur Sleep Res Soc (ESRS) (Sept 4-8, Paris) 2012, Abst O-324.
32. Ivgy-May, N., Liebensperger, H., Froman, S. et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: A 3-month phase 3 trial (trial #2). 21st Congr Eur Sleep Res Soc (ESRS) (Sept 4-8, Paris) 2012, Abst P-988.
33. Herring, W.J., Connor, K., Ivgy-May, N. et al. Efficacy and safety of suvorexant, a dual orexin receptor antagonist, in patients with primary insomnia: Results from two pivotal trials. 26th Annu Meet Assoc Profess Sleep Soc (June 9-16, Boston) 2012, Abst LBA4.
34. Herring, W.J., Snyder, E., Paradis, E. et al. Suvorexant, an orexin receptor antagonist, in preventing symptom return in patients with insomnia after 1 year of treatment: A randomised, double-blind, placebo-controlled study. 21st Congr Eur Sleep Res Soc (ESRS) (Sept 4-8, Paris) 2012, Abst P-987.
35. Herring, W.J, Snyder, E., Paradis, E., Liu, M., Snavely, D., Roth, T., Michelson, D. Long term safety and efficacy of suvorexant in patients with primary insomnia. 26th Annu Meet Assoc Profess Sleep Soc (June 9-16, Boston) 2012, Abst 0641.
36. Herring, W.J., Ma, J.S., Snyder, E. et al. Power spectral profile of the orexin receptor antagonist suvorexant (MK-4305) in primary insomnia patients and healthy-subjects. Biol Psychiatry 2012, 74(8): A942.
37. Shekhar, A., Johnson, P.L. (Indiana University Research and Technology Corp.) Treatment of symptoms associated with menopause. WO 2012044830.
38. Shekhar, A., Johnson, P.L. (Merck & Co., Inc.) Methods and compositions comprising orexin receptor antagonists for treatment of panic disorders. WO 2011050199.
39. Boutrel, B. Hypocretin/orexin receptor antagonism and the promise of anticraving medications: Myth or panacea? J Addict Res Ther 2011, S4: 5-10.
40. Zhou, L., Sun, W.-L., See, R.E. Orexin receptor targets for anti-relapse medication development in drug addiction. Pharmaceuticals 2011, (4): 804-21.